State Street’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $379M | Sell |
5,745,193
-80,102
| -1% | -$5.09M | 0.01% | 647 |
|
|
2025
Q4 | $370M | Buy |
5,825,295
+207,961
| +4% | +$12.9M | 0.01% | 654 |
|
|
2025
Q3 | $309M | Sell |
5,617,334
-755,419
| -12% | -$31.1M | 0.01% | 724 |
|
|
2025
Q2 | $211M | Buy |
6,372,753
+287,752
| +5% | +$10M | 0.01% | 875 |
|
|
2025
Q1 | $245M | Sell |
6,085,001
-82,339
| -1% | -$3.78M | 0.01% | 785 |
|
|
2024
Q4 | $290M | Sell |
6,167,340
-290,984
| -5% | -$15.1M | 0.01% | 733 |
|
|
2024
Q3 | $341M | Sell |
6,458,324
-90,212
| -1% | -$5.03M | 0.01% | 657 |
|
|
2024
Q2 | $355M | Buy |
6,548,536
+2,028,178
| +45% | +$122M | 0.02% | 602 |
|
|
2024
Q1 | $317M | Sell |
4,520,358
-1,373,000
| -23% | -$106M | 0.01% | 660 |
|
|
2023
Q4 | $492M | Buy |
5,893,358
+618,872
| +12% | +$22.4M | 0.02% | 516 |
|
|
2023
Q3 | $155M | Buy |
5,274,486
+182,906
| +4% | +$6.09M | 0.01% | 905 |
|
|
2023
Q2 | $166M | Buy |
5,091,580
+337,680
| +7% | +$12.5M | 0.01% | 891 |
|
|
2023
Q1 | $167M | Sell |
4,753,900
-291,014
| -6% | -$11.9M | 0.01% | 862 |
|
|
2022
Q4 | $231M | Buy |
5,044,914
+789,789
| +19% | +$34M | 0.01% | 695 |
|
|
2022
Q3 | $206M | Sell |
4,255,125
-249,101
| -6% | -$12M | 0.01% | 721 |
|
|
2022
Q2 | $177M | Buy |
4,504,226
+307,394
| +7% | +$12.4M | 0.01% | 803 |
|
|
2022
Q1 | $154M | Buy |
4,196,832
+211,605
| +5% | +$7.52M | 0.01% | 1002 |
|
|
2021
Q4 | $182M | Sell |
3,985,227
-325,061
| -8% | -$12.5M | 0.01% | 915 |
|
|
2021
Q3 | $154M | Buy |
4,310,288
+59,502
| +1% | +$1.75M | 0.01% | 982 |
|
|
2021
Q2 | $84.1M | Buy |
4,250,786
+108,816
| +3% | +$2.56M | ﹤0.01% | 1436 |
|
|
2021
Q1 | $96.3M | Sell |
4,141,970
-498,953
| -11% | -$10.7M | 0.01% | 1263 |
|
|
2020
Q4 | $96.4M | Buy |
4,640,923
+860,663
| +23% | +$15.7M | 0.01% | 1173 |
|
|
2020
Q3 | $81.8M | Buy |
3,780,260
+739,228
| +24% | +$17.3M | 0.01% | 1106 |
|
|
2020
Q2 | $71.7M | Buy |
3,041,032
+355,470
| +13% | +$6.67M | 0.01% | 1194 |
|
|
2020
Q1 | $31.7M | Buy |
2,685,562
+145,796
| +6% | +$1.86M | ﹤0.01% | 1545 |
|
|
2019
Q4 | $26.9M | Buy |
2,539,766
+218,887
| +9% | +$2.25M | ﹤0.01% | 1930 |
|
|
2019
Q3 | $26.4M | Sell |
2,320,879
-95,635
| -4% | -$1.2M | ﹤0.01% | 1879 |
|
|
2019
Q2 | $27.2M | Buy |
2,416,514
+374,437
| +18% | +$3.61M | ﹤0.01% | 1898 |
|
|
2019
Q1 | $16.5M | Buy |
2,042,077
+126,115
| +7% | +$927K | ﹤0.01% | 2168 |
|
|
2018
Q4 | $12.1M | Sell |
1,915,962
-85,600
| -4% | -$628K | ﹤0.01% | 2327 |
|
|
2018
Q3 | $19.7M | Sell |
2,001,562
-43,739
| -2% | -$351K | ﹤0.01% | 2190 |
|
|
2018
Q2 | $17M | Sell |
2,045,301
-316,311
| -13% | -$2.63M | ﹤0.01% | 2241 |
|
|
2018
Q1 | $17M | Sell |
2,361,612
-354,360
| -13% | -$3.04M | ﹤0.01% | 2163 |
|
|
2017
Q4 | $22.1M | Buy |
2,715,972
+880,457
| +48% | +$10M | ﹤0.01% | 1980 |
|
|
2017
Q3 | $26.6M | Buy |
1,835,515
+161,180
| +10% | +$2.2M | ﹤0.01% | 1819 |
|
|
2017
Q2 | $20.3M | Buy |
1,674,335
+741,909
| +80% | +$10.3M | ﹤0.01% | 1969 |
|
|
2017
Q1 | $12M | Buy |
932,426
+34,678
| +4% | +$405K | ﹤0.01% | 2268 |
|
|
2016
Q4 | $10.9M | Sell |
897,748
-75,452
| -8% | -$801K | ﹤0.01% | 2290 |
|
|
2016
Q3 | $8.94M | Buy |
973,200
+349,954
| +56% | +$3.65M | ﹤0.01% | 2245 |
|
|
2016
Q2 | $5.91M | Buy |
623,246
+77,786
| +14% | +$638K | ﹤0.01% | 2499 |
|
|
2016
Q1 | $3.85M | Sell |
545,460
-255,751
| -32% | -$1.87M | ﹤0.01% | 2687 |
|
|
2015
Q4 | $8.38M | Buy |
801,211
+250,173
| +45% | +$2.45M | ﹤0.01% | 2290 |
|
|
2015
Q3 | $3.69M | Buy |
551,038
+1,423
| +0.3% | +$9.71K | ﹤0.01% | 2667 |
|
|
2015
Q2 | $3.69M | Buy |
549,615
+14,282
| +3% | +$93.7K | ﹤0.01% | 2795 |
|
|
2015
Q1 | $3.63M | Buy |
535,333
+26,166
| +5% | +$195K | ﹤0.01% | 2744 |
|
|
2014
Q4 | $4.08M | Buy |
509,167
+5,677
| +1% | +$24.4K | ﹤0.01% | 2675 |
|
|
2014
Q3 | $1.78M | Buy |
503,490
+10,122
| +2% | +$42.5K | ﹤0.01% | 3067 |
|
|
2014
Q2 | $2.36M | Buy |
493,368
+4,194
| +0.9% | +$25.6K | ﹤0.01% | 2986 |
|
|
2014
Q1 | $4.65M | Buy |
489,174
+76,964
| +19% | +$696K | ﹤0.01% | 2606 |
|
|
2013
Q4 | $2.68M | Buy |
412,210
+34,523
| +9% | +$227K | ﹤0.01% | 2929 |
|
|
2013
Q3 | $2.87M | Buy |
377,687
+88,953
| +31% | +$954K | ﹤0.01% | 2862 |
|
|
2013
Q2 | $3.34M | Buy |
+288,734
| New | +$2.27M | ﹤0.01% | 2688 |
|
Other funds holding CYTK
VPM
VCM
ACA
RI
State Street's CYTK Position: Q1 2026 in Review
State Street reduced its Cytokinetics (CYTK) stake by 1.4% in Q1 2026, selling an estimated $5.09M and leaving 5,745,193 shares worth $379M. The position accounts for 0.01% of the portfolio, ranked #647.
State Street first reported a position in CYTK in Q2 2013 and has held it in 52 quarters since. The position peaked at $492M in Q4 2023. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.
- State Street held 5,745,193 shares of Cytokinetics worth $379M as of Q1 2026.
- State Street sold 80,102 Cytokinetics shares in Q1 2026, an estimated $5.09M.
- Cytokinetics made up 0.01% of State Street's portfolio in Q1 2026, its #647 holding.
- State Street first reported a position in Cytokinetics in Q2 2013 and has held it in 52 quarters since.
- State Street's Cytokinetics position peaked at $492M in Q4 2023.
- 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.